Orion profit falls as Parkinson's drug patents expire
HELSINKI, April 23
HELSINKI, April 23 (Reuters) - Finnish drug maker Orion reported a fall in first-quarter profit, in line with expectations, due to the expiration of its patents for Parkinson's drugs.
Orion's quarterly operating profit fell 6 percent from a year earlier to 74 million euros ($96 million), matching the average forecast of analysts in a Reuters poll.
The company repeated it expects a slight fall in full-year 2013 operating profit, and shares in the company fell 0.8 percent to 20.20 euros. ($1 = 0.7674 euros) (Reporting By Jussi Rosendahl)
- U.S. leaders call for 'war' on Ebola outbreak, pledge troops
- Tesla prevails in top Massachusetts court over direct sales
- Russia needs government investment to avoid recession, says former finance minister
- Stocks end higher on bet Fed won't change rate stance
- Ukraine ratifies EU deal, offers special status to rebels